SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (290)7/29/1999 9:22:00 PM
From: Casaubon  Respond to of 1169
 
well, IMO, if Vertex is to be a takeover target, it would likely be a hostile takeover. Josh Boger, the president and CEO of the company, wants Vertex to be the next Merck. This isn't a wild boast, it is his goal. And in fact, the poison pill for Vertex has recently been expanded for just such a contingency.

It looks like Vertex gets about 12.5% royalty on Amprenavir sales.



To: LLCF who wrote (290)7/31/1999 12:04:00 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 1169
 
<<KvE likes VRTX>>

Geze...now I have explanation why VRTX performed as neutral during last few weeks sec-tire bts rally. I guess there are still hot money left.

If KvE can claim that he was not short GILD, MLNM, MEDI,... I may consider few nice words for him???

Nay, it's to early!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News